PubMed Health⌕ Search

Biomedical subjects

Matthias Schier

Publications and source records attributed to Matthias Schier.

3 recordsLinked to original sources

Clinical performance of automatic closed-loop stimulation systems.

Inos pacemakers use contraction dynamics to regulate the pacing rate according to the Closed-Loop Stimulation (CLS) principle. The physician can program only the lower and upper rate limits, while the internal rate responsive parameters are continually adjusted to changing patient conditions. Seventy-two patients with sinus node disease were enrolled in the multicenter Rate Behavior of the Pacing System Inos (2) CLS during Daily Life (RAPID) study to evaluate the appropriateness of CLS rates during daily activities and the long-term stability of the system. The pacemakers clearly differentiated between climbing stairs, descending stairs, and slow walking, with the corresponding peak rates of 104 +/- 18, 95 +/- 15, and 88 +/- 11 beats/min, respectively (P < 0.001 for any pair of activities). The peak CLS rate during the color-word test was significantly higher than that at rest (80 +/- 8 vs 67 +/- 7 beats/min, P = 0.002). The 24-hour heart rate trends retrieved from the pacemaker memory at 3, 6, and 12 months after implantation appeared appropriate in all patients except for two whose pacing rates were occasionally too fast during the night. Mean diurnal and nocturnal rates determined at 3-month, 6-month, and 12-month examinations fluctuated only slightly, from 74.6-75.3 beats/min (diurnal,P = NS) and from 67.0-68.1 beats/min (nocturnal,P = NS), indicating a satisfactory long-term stability of the system. The incidence of atrial pacing events during the entire follow-up was 82 +/- 18%. A 6.5-8.3 beats/min difference, on average, between day and night (P < 0.001)and distinction between different daily activities seem to evidence sensitivity of the automatic CLS-driven pacemakers to physiological demands despite minimum programming requirements.

Activities of Daily Living↗

Rate-adaptive pacing using intracardiac impedance shows no evidence for positive feedback during dobutamine stress test.

BACKGROUND: The Inos2 DDDR pacemaker senses unipolar intracardiac impedance signals for adapting heart rate to meet the haemodynamic needs of physical activity. Theoretically, such pacing devices could be limited by positive feedback since increase in beating frequency per se enhances contractility. We have addressed this problem in patients with chronotropic incompetence who were subjected to a pharmacological stress test. METHODS AND RESULTS: Twelve patients with chronically implanted Inos2 DDDR pacemakers were studied using the standard protocol of stress echocardiography. Most of the patients reached the programmable maximum closed-loop rate during the incremental dobutamine challenge. The time courses for increase in as well as for recovery of heart rate were not different from control patients receiving routine diagnostic stress echocardiography. CONCLUSIONS: In patients implanted with the Inos2 DDDR pacemaker acute stimulation with intravenous dobutamine leads to a robust increase in paced heart rate without any evidence of positive feedback.

Cardiac Pacing, Artificial↗

The road to bioabsorbable stents: reaching clinical reality?

This article provides an overview of the evolution of revascularization devices since Grüntzig's initial introduction of balloon angioplasty in 1977. In-stent restenosis (ISR) is the major shortcoming of conventional (permanent-implant) stent therapy; even with the innovation and promising benefits of drug-eluting stents, management of ISR is very difficult. ISR is mainly caused by the interaction between the blood and the stent surface and a permanent mechanical irritation of the vascular tissue. Thus stenting technology has moved toward the development of temporary implants composed of biocompatible materials which mechanically support the vessel during the period of high risk for recoil and then completely biodegrade in the long term. Preclinical and first clinical experiences with bioabsorbable magnesium stents are discussed.

Absorbable Implants↗